文献速递胸部肿瘤放疗姑息放疗与转移瘤

非小细胞肺癌重度放射性肺炎后继发感染的病原分布与经验性抗菌治疗

Secondary Infections After Diagnosis of Severe Radiation Pneumonitis (SRP) Among Patients With Non-Small Cell Lung Cancer: Pathogen Distributions, Choice of Empirical Antibiotics, and the Value of Empirical Antifungal Treatment.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2021-08-19

该回顾性研究分析1746例接受胸部放疗后发生重度放射性肺炎(SRP)的非小细胞肺癌(NSCLC)患者,44.5%继发肺部感染,最常见病原为鲍曼不动杆菌、肺炎克雷伯菌和铜绿假单胞菌,感染相关死亡占22.4%。不恰当经验性抗菌治疗、细菌/真菌共感染及缺乏经验性抗真菌治疗是感染相关死亡的独立危险因素,经验性抗真菌治疗疗程 cutoff 值为9天。

要点

  • SRP患者继发肺部感染率达44.5%,感染相关死亡占22.4%。
  • 最常见病原为鲍曼不动杆菌、肺炎克雷伯菌和铜绿假单胞菌。
  • 经验性抗真菌治疗至少9天可能改善结局,但需前瞻性验证。

核心结论

  • 对SRP继发肺部感染患者,恰当的经验性抗菌治疗可降低感染相关死亡率,头孢哌酮-舒巴坦可能是合适的抗菌药物。
  • 经验性抗真菌治疗至少9天可能有助于改善结局,但需进一步前瞻性验证。

研究设计与样本

  • 分析继发肺部感染的肺炎发生率、病原菌及耐药特征,通过单因素和多因素分析识别死亡危险因素。
  • 采用森林图和受试者工作特征曲线评估抗真菌药物疗效及疗程相关效应。

主要发现

  • 44.5%(777/1746)的SRP患者诊断为继发肺部感染。
  • 共分离899株细菌,最常见为鲍曼不动杆菌(n=206;27%)、肺炎克雷伯菌(n=200;26.2%)和铜绿假单胞菌(n=104;13.6%)。
  • 上述分离株对碳青霉烯类和头孢哌酮-舒巴坦的耐药率分别为52.7%和32.2%、28.8%和26.4%、23.7%和20.2%。
  • SRP患者感染相关死亡发生率为22.4%。
  • 感染相关死亡的独立危险因素包括体能状态评分差、不恰当经验性抗菌治疗、细菌/真菌共感染及缺乏经验性抗真菌治疗。

关键数值与推荐

  • 继发肺部感染率44.5%(777/1746)。
  • 鲍曼不动杆菌对碳青霉烯类和头孢哌酮-舒巴坦耐药率分别为52.7%和32.2%。
  • 肺炎克雷伯菌对碳青霉烯类和头孢哌酮-舒巴坦耐药率分别为28.8%和26.4%。
  • 铜绿假单胞菌对碳青霉烯类和头孢哌酮-舒巴坦耐药率分别为23.7%和20.2%。
  • 经验性抗真菌治疗疗程cutoff值为9天,曲线下面积0.819。

临床怎么用

  • 对SRP继发肺部感染患者应尽早给予恰当经验性抗菌治疗,头孢哌酮-舒巴坦可考虑作为选择。
  • 评估患者体能状态、细菌/真菌共感染及经验性抗真菌治疗情况以识别感染相关死亡高危患者。
  • 在抗菌药物敏感性试验结果出来前,可考虑经验性抗真菌治疗至少9天以改善结局。

局限性

  • 本研究为回顾性分析,经验性抗真菌治疗疗程的获益需进一步前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aimed to assess pathogen distributions and antimicrobial sensitivity characteristics in patients with non-small cell lung cancer (NSCLC) with severe radiation pneumonitis (SRP) and secondary infections. METHODS AND MATERIALS: Data from 1746 patients with NSCLC and SRP after thoracic radiation therapy from January 2009 to December 2020 were retrospectively analyzed. Pneumonia incidence, causative pathogens, and antibiotic resistance characteristics in patients with secondary lung infections were analyzed. Risk factors associated with mortality were identified through univariate and multivariate analyses. Antifungal drug efficacy and duration-related effects were assessed with Forest plots and receiver operating characteristic curves. RESULTS: Overall, 44.5% of patients with NSCLC and SRP (777 of 1746 patients) were diagnosed with secondary lung infections. In total, 899 bacterial strains were isolated from these patients, with Acinetobacter baumannii (n = 206; 27%), Klebsiella pneumonia (n = 200; 26.2%), and Pseudomonas aeruginosa (n = 104; 13.6%) being the most common. Carbapenem and cefoperazone-sulbactam resistance rates of 52.7% and 32.2%, 28.8% and 26.4%, and 23.7% and 20.2% were observed for these isolates, respectively. Infection-related deaths occurred in 22.4% of patients with SRP. Independent risk factors for infection-related death included poor performance status scores, inappropriate empirical antimicrobial treatment, bacteria/fungal coinfection, and lack of empirical antifungal treatment. Receiver operating characteristic curves showed that the cutoff value of empirical antifungal treatment duration was 9 (area under the curve: 0.819). CONCLUSIONS: For patients with SRP and secondary lung infections, appropriate empirical antimicrobial treatment could decrease infection-related mortality, and cefoperazone-sulbactam may be an appropriate antibacterial drug. Empirical antifungal treatment for a minimum of 9 days might contribute to better outcomes. Although this represents a promising treatment approach for patients with SRP and secondary lung infections before antibacterial susceptibility testing, further prospective validation is essential.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Mei T, Yang X, Yu Y, et al. Secondary Infections After Diagnosis of Severe Radiation Pneumonitis (SRP) Among Patients With Non-Small Cell Lung Cancer: Pathogen Distributions, Choice of Empirical Antibiotics, and the Value of Empirical Antifungal Treatment. Int J Radiat Oncol Biol Phys. 2021. PMID: 34418467. doi:10.1016/j.ijrobp.2021.08.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。